EFFICACY AND SAFETY OF ANTIVIRAL THERAPY IN THE TREATMENT OF VIRAL INFECTIONS
DOI:
https://doi.org/10.5281/zenodo.18312051Keywords:
viral infections, antiviral therapy, efficacy, safety, pharmacodynamics, pharmacokinetics, drug–drug interactions, toxic effects, patient monitoring, individual pharmacogenetics.Abstract
Viral infections represent a significant challenge in modern medicine due to their rapid spread and diverse clinical manifestations, which considerably impact patient health and public health outcomes. Antiviral therapy constitutes an effective pharmacological approach against viral pathogens and plays a critical role in slowing disease progression and reducing complications. This article analyzes the efficacy of antiviral agents, their pharmacodynamic and pharmacokinetic properties, and their application in various viral infections, including those caused by RNA and DNA viruses. Special attention is given to safety aspects of therapy, including dosing, toxic effects, drug–drug interactions, and risks associated with the patient’s individual pharmacogenetic profile. Study findings indicate that the effectiveness of antiviral therapy depends on the virus type, the patient’s clinical condition, and the individualized adaptation of the treatment strategy. Furthermore, patient monitoring and the development of safety protocols are emphasized to minimize adverse effects during long-term therapy.
References
De Clercq, E. Antiviral agents: Past, present and future. Biochemical Pharmacology, 158, 49–67, 2019.
Crotty, S., Cameron, C. E., & Andino, R. RNA virus fidelity: Mechanisms and relevance. Nature Reviews Microbiology, 15(7), 414–424, 2017.
Richman, D. D., Whitley, R. J., & Hayden, F. G. Clinical Virology, 4th Edition. ASM Press, Washington, 2016.
World Health Organization (WHO). Global report on viral infections and antiviral treatment strategies. Geneva: WHO, 2022.
De Clercq, E., & Li, G. Approved antiviral drugs over the past 50 years. Clinical Microbiology Reviews, 29(3), 695–747, 2016.
Choi, Y., et al. Antiviral drug safety and pharmacogenetics: Current perspectives. Pharmacogenomics, 21(10), 725–741, 2020.
Hayden, F. G., & Shindo, N. Antiviral therapy for respiratory virus infections. Antiviral Research, 98, 52–75, 2013.
Pawlotsky, J.-M. Hepatitis C virus resistance to direct-acting antiviral drugs. Gastroenterology, 151(1), 70–86, 2016.
De Clercq, E., & Neyts, J. Antiviral drug discovery and development: Past, present, and future. Antiviral Research, 100, 1–12, 2013.
Tomila, S.A., & Borovik, E.N. Antiviral therapy: Theory and practice. Moscow: Meditsina, 2018, pp. 45–78.
Karimov, S. New antiviral strategies in the treatment of viral infections. Tashkent: Tibbiyot Publishing, 2020, pp. 112–140.
De Clercq, E., & Field, H. J. Pharmacology of antiviral drugs. Annual Review of Pharmacology and Toxicology, 41, 145–185, 2001.
Beigel, J. H., et al. Current and future antiviral therapy for influenza. The Journal of Infectious Diseases, 221(Suppl 1), S26–S36, 2020.
Zhang, L., et al. Advances in antiviral drug design. Current Opinion in Virology, 39, 24–32, 2020.
Tashpulatov, A.T. Antiviral drugs and their clinical application. Samarkand: SamDTI Publishing, 2019, pp. 60–95.
Whitley, R. J., & Gnann, J. W. Antiviral therapy for herpesvirus infections. The New England Journal of Medicine, 350, 2000–2008, 2004.
Götte, M. Mechanisms of antiviral drug resistance. The Journal of Clinical Virology, 75, 37–41, 2016
